ORIGINAL ARTICLE
LEVELS OF MONOCYTE CHEMOATTRACTANT PROTEIN-1
DIFFER FROM THE NORM IN PATIENTS WITH SUDDEN
SENSORINEURAL HEARING LOSS
| 1 | Department of Otorhinolaryngology, University of Regensburg, Germany |
| 2 | Department of Otorhinolaryngology, University of Zurich, Switzerland |
CORRESPONDING AUTHOR
Frank Haubner
Frank Haubner, Department of Otorhinolaryngology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany, Phone: +49-941-9449515, Fax: +49-941-9449415, e-mail: frank.haubner@klinik.uni-regensburg.de
Frank Haubner, Department of Otorhinolaryngology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany, Phone: +49-941-9449515, Fax: +49-941-9449415, e-mail: frank.haubner@klinik.uni-regensburg.de
Publication date: 2020-04-20
J Hear Sci 2012;2(1):36–40
ABSTRACT
Background:
The aim of this study was to evaluate the role of cytokines and soluble adhesion molecules in patients with sudden sensorineural hearing loss (SSNHL) with respect to their pure-tone audiometry values.
Material and Methods:
This study analyses blood samples of 51 patients with SSNHL. Serum levels of ICAM-1, VCAM-1, E-selectin, IL-6, IL-8, and MCP-1 were evaluated by ELISA. Pure-tone audiometry data were compared before and after a systemic steroid treatment regimen. The subjects with SSNHL were compared to a control group of 44 patients with normal hearing and matching age and gender. The data complete our previous data collection.
Results:
There is trend toward suppressed levels of MCP-1 in sera of SSNHL patients. There were no statistically significant differences concerning ICAM-1, VCAM-1, E-selectin, IL-6, IL-8, and MCP-1 between SSNHL patients and controls. Puretone audiometry of the SSNHL group showed a significant improvement in hearing after systemic steroid therapy and a median follow-up of 4 months.
Conclusions:
Further prospective studies are necessary to prove the role of MCP-1 and other cytokines in SSNHL in order to develop adequate treatment regimens.
The aim of this study was to evaluate the role of cytokines and soluble adhesion molecules in patients with sudden sensorineural hearing loss (SSNHL) with respect to their pure-tone audiometry values.
Material and Methods:
This study analyses blood samples of 51 patients with SSNHL. Serum levels of ICAM-1, VCAM-1, E-selectin, IL-6, IL-8, and MCP-1 were evaluated by ELISA. Pure-tone audiometry data were compared before and after a systemic steroid treatment regimen. The subjects with SSNHL were compared to a control group of 44 patients with normal hearing and matching age and gender. The data complete our previous data collection.
Results:
There is trend toward suppressed levels of MCP-1 in sera of SSNHL patients. There were no statistically significant differences concerning ICAM-1, VCAM-1, E-selectin, IL-6, IL-8, and MCP-1 between SSNHL patients and controls. Puretone audiometry of the SSNHL group showed a significant improvement in hearing after systemic steroid therapy and a median follow-up of 4 months.
Conclusions:
Further prospective studies are necessary to prove the role of MCP-1 and other cytokines in SSNHL in order to develop adequate treatment regimens.
REFERENCES (18)
1.
Ohinata Y, Makimoto K, Kawakami M et al: Blood viscosity and plasma viscosity in patients with sudden deafness. Acta Otolaryngol, 1994, 114(6): 601–7.
2.
Nagaoka J, Anjos MF, Takata TT et al: Idiopathic sudden sensorineural hearing loss: evolution in the presence of hypertension, diabetes mellitus and dyslipidemias. Braz J Otorhinolaryngol, 76(3): 363–69.
3.
Canis M, Heigl F, Hettich R et al: [Fibrinogen/LDL apheresis for treatment of sudden hearing loss: An observational study on 152 patients.]. Hno, 2008, 56(9): 961–66.
4.
Adams JC: Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol, 2002, 23(3): 316–22.
5.
Quaranta N, Ramunni A, Brescia P et al: Soluble intercellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1 in sudden hearing loss. Otol Neurotol, 2008, 29(4): 470–74.
6.
Yadav A, Saini V, Arora S: MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta, 2010, 411(21–22): 1570–79.
7.
Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL: Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol, 2009, 41(5): 998–1001.
8.
Haubner F, Martin L, Steffens T et al: The role of soluble adhesion molecules and cytokines in sudden sensorineural hearing loss. Otolaryngol Head Neck Surg, 2011; 144(4): 575–80.
9.
Takebayashi K, Suetsugu M, Matsumoto S et al: Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J, 2009, 102(4): 361–68.
10.
Lukacs NW, Strieter RM, Elner V et al: Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood, 1995; 86(7): 2767–73.
11.
Moon SK, Woo JI, Lee HY et al: Toll-like receptor 2-dependent NF-kappaB activation is involved in nontypeable Haemophilus influenzae-induced monocyte chemotactic protein 1 up-regulation in the spiral ligament fibrocytes of the inner ear. Infect Immun, 2007; 75(7): 3361–72.
12.
Moon SK, Park R, Lee HY et al: Spiral ligament fibrocytes release chemokines in response to otitis media pathogens. Acta Otolaryngol, 2006; 126(6): 564–69.
13.
Ogino K, Kato M, Furuse Y et al: Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without beta-blockers. Circ J, 2010; 74(11): 2346–52.
14.
Tretjakovs P, Jurka A, Bormane I et al: Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. Eur J Intern Med, 2009; 20(7): 712–17.
15.
Bianchi LM, Daruwalla Z, Roth TM et al: Immortalized mouse inner ear cell lines demonstrate a role for chemokines in promoting the growth of developing statoacoustic ganglion neurons. J Assoc Res Otolaryngol, 2005; 6(4): 355–67.
16.
Schreiber BE, Agrup C, Haskard DO, Luxon LM: Sudden sensorineural hearing loss. Lancet, 2010, 375(9721): 1203–11.
17.
Gordin A, Goldenberg D, Golz A et al: Magnesium: a new therapy for idiopathic sudden sensorineural hearing loss. Otol Neurotol, 2002; 23(4): 447–51.
18.
Chau JK, Lin JR, Atashband S et al: Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope, 2010, 120(5): 1011–21.
